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Abstract
Background: Proxy respondents are frequently used in surveys, including those assessing health-related quality of life
(HRQOL). In cancer, most research involving proxies has been undertaken with paired proxy-patient populations, where
proxy responses are compared to patient responses for the same individual. In these populations, proxy-patient
differences are small and suggest proxy underestimation of patient HRQOL. In practice, however, proxy responses will
only be used when patient responses are not available. The difference between proxy and patient reports of patient
HRQOL where patients are not able to report for themselves in cancer is not known. The objective of this study was to
evaluate the difference between patient and proxy reports of patient HRQOL in a large national cancer survey, and
determine if this difference could be mitigated by adjusting for clinical and sociodemographic information about patients.
Methods: Data were from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Patients or their
proxies were recruited within 3–6 months of diagnosis with lung or colorectal cancer. HRQOL was measured using the
SF-12 mental and physical composite scales. Differences of ½ SD (=5 points) were considered clinically significant. The
primary independent variable was proxy status. Linear regression models were used to adjust for patient
sociodemographic and clinical covariates, including cancer stage, patient age and education, and patient co-morbidities.
Results: Of 6471 respondents, 1011 (16%) were proxies. Before adjustment, average proxy-reported scores were lower for
both physical (−6.7 points, 95% CI -7.4 to −5.9) and mental (−6 points, 95% CI -6.7 to −5.2) health. Proxy-reported scores
remained lower after adjustment (physical: −5.8 points, −6.6 to −5; mental: −5.8 points, −6.6 to 5). Proxy-patient score
differences remained clinically and statistically significant, even after adjustment for sociodemographic and clinical
variables.
Conclusions: Proxy-reported outcome scores for both physical and mental health were clinically and significantly lower
than patient-reported scores for these outcomes. The size of the proxy-patient score differences was not affected by the
health domain, and adjustment for sociodemographic and clinical variables had minimal impact.
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Background
Patient-reported outcomes (PROs) are increasingly im-
portant in oncology. The Medicare Health Outcomes
Survey (MHOS) collects health-related quality of life
(HRQOL) and other PRO information from respon-
dents, which is used in the calculation of publicly
reported health plan star ratings [1]. Additionally, the
National Quality Forum is working to develop PRO
performance measures [2]. In oncology, PRO performance
measures assessing symptom management processes and
outcomes are being actively explored [3, 4].
A major challenge associated with PROs is that patients
may be too ill to complete questionnaires. In diseases such
as cancer, severely ill patients may comprise a large por-
tion of the study population. Evaluation of the potential
for proxy reporters to answer on the patient’s behalf in
cancer was primarily conducted using paired studies that
include data from proxy-patient dyads [5]. The findings
from paired studies evaluating proxy-patient differences
and correlations in cancer suggest that proxy-patient dif-
ferences tend to be small on average and correlations are
at least moderate [6–8]. It is not known how well the
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findings from paired proxy-patient studies will map to un-
paired studies, as patients in the latter group are unable to
complete questionnaires and thus may differ in important,
systematic ways from patients who are able to complete
questionnaires. Furthermore, proxies will only be used in
practice if patients are unable to complete questionnaires,
and thus understanding the differences in this practical
context is important.
This question takes on greater importance in light of
the many surveys used for public reporting and health
policy decision-making that employ proxies to report on
behalf of an otherwise missing patient and evaluate the pa-
tient’s health status and HRQOL. This includes the Behav-
ioral Risk Factor Surveillance System (BRFSS) [9], MHOS
[10, 11], and the National Health Interview Survey (NHIS)
[12, 13]. Results from survey populations using proxies to
substitute for otherwise missing patients have found that
proxies underestimate the prevalence of disease [14, 15]
and disability [12], although casemix adjustment may be
able to reduce this bias in some cases [13].
To date, few studies in cancer have evaluated the dif-
ferences between proxy and patient reports in unpaired
studies, where proxies are more likely to be needed and
used. It is also important to determine whether any dif-
ferences found can be reduced through adjustment for
clinical and sociodemographic characteristics, as such
characteristics are frequently collected in surveys.
Because HRQOL is an important outcome in cancer,
particularly advanced cancer, and a high rate of proxy
use can be anticipated due to the nature of disease and
treatment, understanding the size of the proxy-patient
difference and the potential for mitigating it using rou-
tinely collected data is important. We therefore evalu-
ated 1) the size and direction of the difference between
proxy and patient reports of patient HRQOL in a large,
population-based representative survey of cancer
patients; and 2) whether this difference was affected by
adjustment for frequently used sociodemographic and
clinical covariates. We hypothesized that the use of
proxies would be driven by poor patient health, and that
proxy HRQOL responses would therefore be consist-
ently lower than patient responses.
Methods
Study setting, participants and data sources
The Cancer Care Outcomes Research and Surveillance
(CanCORS) study is a large, clinically and demographically
representative [16] study of patients with incident lung or
colorectal cancer. CanCORS evaluated a number of PROs,
including care experience and quality rating [17, 18] and
shared decision-making [19–21]. The design and conduct
of the study has been reported previously [17, 18, 22]. Pa-
tients were enrolled from 2003 to 2005 using rapid case as-
certainment from several geographic regions and health
systems [18, 19]. Computer-adapted telephone interviewing
was used to survey patients, or their proxies if patients were
unable to respond or had died, approximately 3 to 6
months post diagnosis. If patients were not able to re-
spond, they were asked if a proxy could answer on
their behalf, and to nominate someone who was
knowledgeable about their condition and care. Beyond
being nominated by a patient, no further eligibility
criteria were placed on proxies. Partial, brief or self-
administered surveys were also offered if needed.
Sociodemographic information, the presence or absence
of co-morbidities, and reports of care experiences, care
quality, cancer symptoms, and health-related quality of life
were solicited through the computer-adapted telephone
interview. Trained abstractors extracted information on
patient cancer stage from medical records [18]. If medical
records were not available, American Joint Committee on
Cancer (AJCC) stage or historical stage (local/regional/dis-
tant) was obtained from cancer registries. Questionnaire in-
struments were based on previously validated or employed
instruments [22]. The American Association for Public
Opinion Research [16] survey response rate was 51.0% and
the cooperation rate was 59.9%. Institutional review boards
at all participating institutions approved the study and writ-
ten or verbal informed consent was obtained depending on
the study site.
For this analysis, we restricted the study sample to
patients and proxies of living patients who completed the
full baseline telephone survey (Fig. 1, n = 6471). All patients
in our analytic sample were alive at the time of the survey.
Outcome measures/dependent variables
HRQOL in CanCORS was assessed using questions from
the 12-item Short Form (SF-12, version 2) [22], a vali-
dated and widely adopted generic HRQOL tool [23].
Proxy and patient questions for the SF-12 were identical,
except for patients being asked about “your” health and
proxies being asked about “the patient’s” health.
The SF-12 includes 12 questions that cover eight do-
mains: general health, physical function, role-physical,
role-emotional, bodily pain, mental health, vitality, and so-
cial function (Appendix: Table 4). All but one of the SF-12
items ask respondents to refer to the past 4 weeks when
answering. Three and five point scales are used for item
scores. Scoring through T-scores using US general popula-
tion means and standard deviations and weighting pro-
duces two composite scales: the physical (PCS) and the
mental (MCS). Both scales are calculated using each item,
albeit with different weights; thus, missingness in any one
item can result in the full scale being missing for that ob-
servation. These scales range from 0 (worst) to 100 (best),
with normalized standardized T-score means of 50 and
standard deviations of 10. Score differences of ½ SD (=5
points) are often treated as clinically significant [24, 25].
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Independent variable and covariates: The adjustment
model
In our primary analyses, our independent variable was
an indicator for proxy (0/1). The use of an indicator
variable for respondent status as part of a regression
model is a frequently used approach for accounting for
proxy-reported data [11, 26]. We also added several
“standard” clinical and sociodemographic covariates,
based on the casemix model used for the MHOS, a large
national survey of HRQOL that allows for proxy respon-
dents. Because MHOS is not cancer-specific, we also
adjusted for cancer type (lung or colorectal) and disease
curability (incurable/potentially curable). Incurable dis-
ease was defined as AJCC stage IIIB or IV, distant stage,
or unstaged for lung cancer and AJCC stage IV, distant
stage, or unstaged for colorectal cancer. We included
this information as disease stage has been shown to be a
predictor of HRQOL in patients with cancer [27, 28].
Our regression models adjusted for several patient
sociodemographic characteristics, all of which have been
previously shown to predict HRQOL in patients with
cancer or cancer survivors: gender [27, 29], marital sta-
tus [30], race/ethnicity [30], age [29], and educational at-
tainment [31], all of which were solicited during the
telephone interview and provided either by the patient,
describing themselves (in a patient interview) or the
proxy, describing the patient (in a proxy interview).
Understanding variation in patient experience by race/
ethnicity was a goal of CanCORS [18]. Race/ethnicity
was collected using the U.S. Census variables. For this
analysis, race/ethnicity was included for consistency with
MHOS casemix [32]. We also adjusted for CanCORS
study site. The separate models for the two primary
outcomes (PCS and MCS) were examined. We also
compared adjusted and unadjusted proxy-patient
differences for each individual subscale (general health,
physical function, role physical, role emotional, bodily
pain, mental health, vitality, and social function). Be-
cause all subscales are combined in the PCS and MCS
calculation, we evaluated the subscales to ensure that no
single subscale had significant influence on our results.
Finally, we adjusted for the presence of comorbidities, as
comorbidities have also been predictors of HRQOL in pa-
tients and survivors [28, 33, 34]. Our analyses adjusted for
each of the following patient comorbidities: coronary ar-
tery disease (heart attack and/or bypass), heart failure,
stroke, arterial bypass, lung disease (asthma, bronchitis,
emphysema, or other chronic lung conditions), diabetes/
high blood sugar, kidney problem, depression (or other
emotional, nervous, or psychiatric problems), previous
cancer, and hospitalization within the last year. In patient
surveys, these comorbidities were reported by the patient
[35], but in proxy surveys the proxy reported whether or
not the patient had the comorbidities in question.
Although we felt that it was possible that proxy char-
acteristics could influence their reports of patient
HRQOL, most surveys that collect proxy data do not
collect proxy characteristics or adjust for them in
Fig. 1 Study Sample Selection Flow Diagram
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models. Thus, to be consistent with our goal of examin-
ing proxy-patient differences after adjustment for fre-
quently used covariates, we did not include proxy
characteristics in our models. However, to provide con-
text we report the most common types of proxy-patient
relationships, determined via the proxy questionnaire.
Statistical analyses
The PCS and MCS were modeled separately for all ana-
lyses. Unadjusted patient-proxy differences in mean
HRQOL scores were obtained using t-tests. Multivari-
able linear regression models with all independent
variables were used for adjusted analyses. Predicted mar-
ginal means were calculated for proxies and patients for
each outcome. The assumptions of the linear regression
models were evaluated using residuals vs predicted plots,
Q-Q plots of residuals, and Cook’s d values. Between-
respondent comparisons of covariates were conducted
using chi-square tests. All significance tests were
performed at the α = 0.05 level, and all analyses were
conducted using SAS v9.4.
Missing data
Multiple imputation (MI) was used for missing data. Miss-
ing data in CanCORS were imputed using sequential re-
gression multiple imputation in IVEware [36]. The
coefficient of determination (R2) was estimated in each of
the imputed datasets separately and combined using
Harel’s formula [37, 38]. The contribution of variables to
the model was evaluated using the multiple partial F-test
for MI data [39]. These calculations were performed in R
Studio (version 3.2.2). We defined the analytic cohort as
respondents with complete covariates. Responses such as
“not applicable” or “refused” were treated as incomplete
and excluded, resulting in an analytic cohort of N = 6426.
For individual items in the SF-12, any non-numeric or
“n/a” response is treated as missing, because it cannot
be validly summed as part of the composite score. These
items are excluded from the calculation, resulting in
missing scales for the respondents [40]. Within the ana-
lytic cohort, excluded items were infrequent; N = 6422/
6426 (99.9% of the analytic cohort and 99.2% of the
study sample) had valid, numeric responses for all items
and the corresponding PCS and MCS scales.
Sensitivity analyses
We conducted several sensitivity analyses. First, we eval-
uated the impact of including unstaged patients in our
models by estimating the models with these patients
excluded. Second, we analyzed the robustness of the re-
sults when variables were added or removed from the
regression models. For the robustness check, we evalu-
ated the impact of adding wealth (number of months
patients could live on their savings), to approximate
income; this variable has been used previously in
CanCORS analyses [41, 42]. We also evaluated the im-
pact of adding survey timing relative to diagnosis. Next,
we evaluated the impact of removing the following vari-
ables: 1) all co-morbidities, including hospitalization; 2)
hospitalization only.
Third, we implemented our primary models using
complete case analysis for missing data rather than the
multiply imputed datasets; the complete case analysis
approach has been used in several studies evaluating
HRQOL in MHOS respondents with cancer [43–45].
Fourth, we evaluated the impact of proxy reports of
patient comorbidities on the relationship between co-
morbidities and HRQOL outcomes in the primary
model. Because proxies may report patient conditions
such as depression differently than patients [46, 47], we
compared the coefficients for all comorbidities in the
primary model under three scenarios: 1) with both pa-
tient- and proxy-reported data and an indicator variable
for proxy status; 2) with both patient- and proxy-
reported data and no indicator variable for proxy status;
3) with patient-reported data only. Lastly, as noted pre-
viously we also checked that our results were not
disproportionately influenced by a single subscale by
testing proxy-patient differences at the subscale level.
Results
Among 6471 participants, 1011 (16%) were proxies.
Most proxies were the patient’s spouse/partner (50%) or
child (36%). Patients with proxy reporters had similar
proportions of the different cancer types but were more
likely to have incurable disease (40.6% vs 30.8%), were
older, and were less educated (Table 1). Patients with
proxy reporters also had more comorbidities and were
more likely to have been hospitalized in the preceding
year (26.0% vs 19.9%). For comorbidities, the greatest
difference was observed for stroke (proxy report: 17.4%,
patient report: 8.3%).
In unadjusted analyses, proxy-reported PCS and MCS
scores were clinically and statistically significantly lower.
Proxy-reported PCS scores were 6.65 points lower on
average (95% CI -7.42 to −5.88). On the PCS, the aver-
age proxy-reported score was 33.56 (SE = 0.36), versus
an average patient-reported score of 40.21 (SE = 0.15).
Proxy-patient differences for the MCS were slightly
smaller but still large: average proxy scores were 5.96 points
lower (95% CI -6.74 to −5.19). On the MCS, the mean
scores were 44.73 (SE = 0.36) and 50.69 (SE = 0.16). For the
subscales, proxy-patient differences ranged from −5.4
points (bodily pain) to −8.9 points (physical function);
differences of 5 points or greater were seen in either the
point estimate or confidence interval of all subscales.
Adjustments using sociodemographic and clinical
covariates had minimal effect on proxy coefficient
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Table 1 Study sample characteristics: Observed data (N = 6471)
Characteristic Overall N (%) Proxy-Reported N (%) Patient-Reported N(%) P-value
Respondent type
Proxy 1011 (15.6) 1011 (100) 5460 (100) N/A
Patient 5460 (84.4)
Patient cancer type
Colorectal cancer 2907 (44.9) 485 (48.0) 2422 (44.4) 0.0339
Lung cancer 3564 (55.1) 526 (52.0) 3038 (55.6)
Patient disease stage/curabilitya
Incurable 2089 (32.3) 410 (40.6) 1679 (30.8) <0.0001
Potentially curable 4382 (67.7) 601 (59.5) 3781 (69.3)
CanCORS site
1 933 (14.4) 65 (6.4) 868 (15.9) <0.0001
2 1345 (20.8) 206 (20.4) 1139 (20.9)
3 857 (13.2) 238 (23.5) 619 (11.3)
4 1359 (21.0) 209 (20.7) 1150 (21.1)
5 567 (8.8) 75 (7.4) 492 (9.0)
6 755 (11.7) 124 (12.3) 631 (11.6)
7 655 (10.1) 94 (9.3) 561 (10.3)
Patient gender
Male 3590 (55.5) 680 (67.3) 2910 (53.3) <0.0001
Female 2881 (44.5) 331 (32.7) 2550 (46.7)
Patient marital status
Married/partnered 4003 (61.9) 643 (63.6) 3360 (61.5) 0.1890
Single/divorced/widowed/never married/separated 2433 (37.6) 361 (35.7) 2072 (38.0)
Missing (blank/refused/unknown) 35 (0.5) 7 (0.7) 28 (0.5)
Patient race/ethnicity
White 4400 (68.0) 599 (59.3) 3801 (69.6) <0.0001
Hispanic 479 (7.4) 108 (10.7) 371 (6.8)
Black 886 (13.7) 160 (15.8) 726 (13.3)
Asian (including Native Hawaiian) 370 (5.7) 97 (9.6) 273 (5.0)
Other (including Native American, multiracial) 322 (5.0) 44 (4.4) 278 (5.1)
Missing (unknown) 14 (0.2) 3 (0.3) 11 (0.2)
Patient age
< =59 years old 1980 (30.6) 131 (13.0) 1849 (33.9) <0.0001
60–69 years old 1827 (28.2) 237 (23.4) 1590 (29.1)
70–79 years old 1771 (27.4) 330 (32.6) 1441 (26.4)
80+ years old 893 (13.8) 313 (31.0) 580 (10.6)
Patient educational attainment
< High school (<12th grade completed) 1331 (20.6) 410 (40.6) 921 (16.9) <0.0001
High school/vocational/some college (<4 years) 3603 (55.7) 445 (44.0) 3158 (57.8)
College (4 years or degree)/postgraduate 1464 (22.6) 120 (11.9) 1344 (24.6)
Missing (blank/refused/unknown/not applicable) 73 (1.1) 36 (3.6) 37 (0.7)
Patient hospitalization in prior year
No 5035 (77.8) 723 (71.5) 4312 (79.0) <0.0001
Yes 1348 (20.8) 263 (26.0) 1085 (19.9)
Missing (blank/refused/unknown/not applicable) 88 (1.4) 25 (2.5) 63 (1.2)
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estimates, resulting in clinically and statistically signifi-
cant proxy-patient conditional differences (Table 2).
Similarly, for all subscales, conditional differences of at
least 5 points remained after adjustment. Model diag-
nostics did not indicate severe violations of the multi-
variate linear regression assumptions.
In sensitivity analyses (Table 2), excluding unstaged
patients had only small effects on the average proxy
scores, with changes of 0.10–0.30 points depending on
the outcome. Adjusting for wealth did not substantially
reduce the gap between proxy and patient scores for
both PCS and MCS models, although this variable was
statistically different from zero for both outcomes (F <
0.05 for both). With wealth included, proxy-patient con-
ditional differences for both outcomes remained clinic-
ally and statistically different: proxy PCS scores were
5.72 points lower on average (95% CI -6.51 to −4.94)
and proxy MCS scores were 5.77 points lower on aver-
age (95% CI -6.56 to −4.98). Similarly, adjusting for
survey timing had a minimal effect on conditional
Table 1 Study sample characteristics: Observed data (N = 6471) (Continued)
Characteristic Overall N (%) Proxy-Reported N (%) Patient-Reported N(%) P-value
History of arterial bypass
No 6106 (94.4) 929 (91.9) 5177 (94.8) 0.0049
Yes 280 (4.3) 60 (5.9) 220 (4.0)
Missing (blank/refused/unknown/not applicable) 85 (1.3) 22 (2.2) 63 (1.2)
History of coronary artery disease (heart attack and/or bypass)
No 5314 (82.1) 772 (76.4) 4542 (83.2) <0.0001
Yes 1096 (16.9) 228 (22.6) 868 (15.9)
Missing (blank/refused/unknown/not applicable) 61 (0.9) 11 (1.1) 50 (0.9)
History of heart failure
No 5955 (92.0) 875 (86.6) 5080 (93.0) <0.0001
Yes 408 (6.3) 112 (11.1) 296 (5.4)
Missing (blank/refused/unknown/not applicable) 108 (1.7) 24 (2.4) 84 (1.5)
History of stroke
No 5754 (88.9) 816 (80.7) 4938 (90.4) <0.0001
Yes 628 (9.7) 176 (17.4) 452 (8.3)
Missing (blank/refused/unknown/not applicable) 89 (1.4) 19 (1.9) 70 (1.3)
Chronic lung disease
No 4906 (75.8) 723 (71.5) 4183 (76.6) 0.0039
Yes 1451 (22.4) 259 (25.6) 1192 (21.8)
Missing (blank/refused/unknown/not applicable) 114 (1.8) 29 (2.9) 85 (1.6)
Diabetes
No 5225 (80.7) 772 (76.4) 4453 (81.6) 0.0004
Yes 1170 (18.1) 221 (21.9) 949 (17.4)
Missing (blank/refused/unknown/not applicable) 76 (1.2) 18 (1.8) 58 (1.1)
History of kidney problems
No 5727 (88.5) 879 (86.9) 4848 (88.8) 0.2488
Yes 650 (10.0) 111 (11.0) 539 (9.9)
Missing (blank/refused/unknown/not applicable) 94 (1.5) 21 (2.1) 73 (1.3)
History of depression/psychological problems
No 4964 (76.7) 749 (74.1) 4215 (77.2) 0.1117
Yes 1421 (22.0) 239 (23.6) 1182 (21.7)
Missing (blank/refused/unknown/not applicable) 86 (1.3) 23 (2.3) 63 (1.2)
History of previous cancer
No 5158 (79.7) 785 (77.7) 4373 (80.1) 0.1068
Yes 1236 (19.1) 211 (20.9) 1025 (18.8)
Missing (blank/refused/unknown/not applicable) 77 (1.2) 15 (1.5) 62 (1.1)
aFor lung cancer, incurable was considered AJCC staging IIIB or above, non-AJCC staging of distant, or unstaged; for CRC, incurable was considered AJCC staging
IV, non-AJCC staging of distant, or unstaged
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proxy-patient differences. The coefficient for survey
timing was statistically different from zero for PCS (F <
0.05) but not for MCS (F > 0.05). In both cases, the point
estimate for the average conditional difference changed
only slightly; the proxy-patient conditional difference in-
creased by 0.13 points for PCS and 0.04 points for MCS.
Sensitivity analyses that excluded comorbidities and
hospitalization (Table 3) showed that models including
these covariates were significantly more effective in predict-
ing both outcomes (F-tests of p < 0.05 for both outcomes
for these analyses). Excluding co-morbidities and
hospitalization exacerbated proxy-patient differences for
both PCS and MCS outcomes; proxy-patient conditional
differences increased by 0.53 points for PCS and 0.71 points
for MCS. Including co-morbidities but not hospitalization
resulted in an increased proxy-patient conditional differ-
ence of 0.04 points for PCS and 0.02 points for MCS.
The results from the primary analysis were similar when
complete case analysis rather than analysis of multiply im-
puted data was used (data not shown). Finally, the associa-
tions between comorbidities and HRQOL scores were
similar whether or not proxy data were included (Table 3).
Discussion
In a large national survey of cancer patients in which proxy
reports were used to substitute for unavailable patient re-
ports, proxy and patient reports of patient HRQOL had
large, clinically relevant differences. Proxy-reported scores
were significantly lower than patient scores, indicating
worse HRQOL. Furthermore, these differences persisted
even after adjustment for clinical and sociodemographic
covariates, and changes to the covariates that were included
in model had minimal effects. These findings were also
robust to different approaches for addressing missing data.
In contrast to previous paired proxy-patient studies in
cancer that found only small differences in proxy and
patient-reported HRQOL, we found that differences
between patient and proxy reports of patient HRQOL
were relatively large. For example, Tang and McCorkle’s
review of proxy-patient concordance studies in
terminally-ill cancer patients found that most studies
had small mean differences for physical HRQOL dimen-
sions, with moderate differences seen for more subject-
ive HRQOL aspects such as fatigue and emotional
function [6]. Similarly, Sneeuw and colleagues’ review of
proxy-patient dyad studies in a range of disease groups,
including cancer, found generally small differences be-
tween proxy-patient pairs, and only saw more extreme
differences in studies with small sample sizes [7]. How-
ever, in a study with a large sample size we found rela-
tively large and clinically important differences for both
mental and physical dimensions of HRQOL. This sug-
gests that proxies in our study may represent a sicker
population. Patients who were too ill to participate in a
lengthy interview may have requested that a proxy
complete the interview on their behalf. It is possible that
the covariates that were collected in the CanCORS sur-
vey and used in our model did not adequately capture
this decision. Additional information, such as the reason
for non-response and the rationale for nominating a spe-
cific person as a proxy, may have been helpful and could
potentially be considered in future studies. Another pos-
sibility is that this difference may be due to proxy bias.
Schwarz and Wellens suggest that proxy reporters use
different sources of information when making reports
compared to individuals making a self-report [48]; in
this vein, Snow and colleagues note that because patients
know more about themselves than proxies do, proxy bias
should be larger for less observable constructs [49]. In
our study, however, we found that proxy-patient differ-
ences were similar for both physical and mental health.
Future qualitative research that investigates the pro-
cesses and decision-making involved in proxy reporting
may be beneficial in addressing some of these issues.
Our findings of similar levels of proxy-patient differ-
ences for physical and mental health outcomes are not
completely consistent with evaluations of proxy response
bias among elderly Medicare patients. Using the Medicare
Table 2 Proxy-patient differences for health-related quality of life outcomes
Model type Physical Composite Scale Score Mental Composite Scale Score
N R2 95% CI Coefficient 95% CI N R2 95% CI Coefficient 95% CI
Unadjusted (proxy variable as
sole covariate)
6422 0.04 0.04–0.05 −6.65 −7.42 to −5.88 6422 0.03 0.03–0.04 −5.96 −6.74 to −5.19
Full casemix model, minus comorbidities
and recent hospitalization
6422 0.12 0.12–0.13 −6.32 −7.13 to −5.53 6422 0.09 0.08–0.09 −6.54 −7.36 to −5.72
Full casemix model with comorbidities,
minus recent hospitalization
6422 0.16 0.15–0.18 −5.83 −6.61 to −5.04 6422 0.16 0.15–0.17 −5.85 −6.64 to −5.05
Full casemix model 6422 0.17 0.16–0.18 −5.79 −6.57 to −5.00 6422 0.16 0.15–0.17 −5.83 −6.62 to −5.03
Full casemix model, without unstaged
patientsa
6087 0.17 0.16–0.18 −5.62 −6.43 to −4.81 6087 0.16 0.15–0.17 −5.54 −6.36 to −4.73
Full casemix model plus wealth 6422 0.18 0.17–0.19 −5.72 −6.51 to −4.94 6422 0.17 0.16–0.18 −5.77 −6.56 to −4.98
Full casemix model plus survey timingb 6420 0.17 0.16–0.18 −5.92 −6.71 to −5.13 6420 0.16 0.15–0.17 −5.87 −6.67 to −5.07
aN = 335 individuals in the analytic cohort were unstaged; bN = 2 individuals had missing survey timing information and therefore N = 6420 were included in this analysis
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Current Beneficiary Survey, Li and colleagues found
higher levels of proxy-patient difference for less observ-
able domains, such as cognitive abilities, and lower levels
for more observable domains such as mobility, with no
significant differences found for highly observable
domains such as seeing or eating solid foods [50]. These
differences were obtained from a propensity-matched ana-
lysis, accounting for sociodemographic variables such as
age and gender as well as clinical information such as the
Charlson Comorbidity Index. Our analysis did not use
propensity score matching, but adjusted for several co-
morbidities as well as for information about disease type
and stage as well as socio-demographics in a regression
model. One possible explanation is that these co-
morbidities may be less important in predicting health sta-
tus for patients with cancer; it is likely that cancer, rather
than, for example, a history of heart failure, is the more
proximal driver of poorer health status. Another possibil-
ity is that the choice of measurement tool may be a factor.
For example, Ellis and colleagues assessed patient-proxy
differences among MHOS respondents using the SF-36,
and found unadjusted patient scores to be approximately
7 points higher than unadjusted proxy scores for both the
PCS and MCS [10]. These differences are consistent with
our findings, although relatively few of the respondents in
Ellis et al.’s analysis had cancer.
Although previous studies have found discrepancies be-
tween proxy and patient reports of comorbidities such as
depression [46], the proportion of patients with depression
was similar for both proxy- and patient-reported data in
our analyses. Furthermore, in our data, the impact of co-
morbidities on HRQOL was the same regardless of whether
or not proxy-reported data were included. One explanation
for this may be that while proxy-reported rates of comor-
bidities were higher, the distribution of comorbidities was
roughly similar between respondent types for most of the
included comorbidities. Additionally, with the exception of
depression in the model for the mental health composite
outcome, the average difference in HRQOL between re-
spondents with and without a given comorbidity was rela-
tively small and not clinically significant (<5 points).
Alternately, our measure of comorbidity, which assessed
the presence of comorbidity but not its severity, may have
been insufficiently sensitive to capture comorbidities that
were severe enough to impact HRQOL.
Conclusions regarding the impact of proxy reporting in
surveys have varied, possibly due to the different outcomes
for which proxy respondents have been employed. Some
analyses have found the impact of including proxy reports
in surveys to be minimal [51] so adjustment can be effective
in minimizing proxy-introduced impact [13], but others
found that further information about proxies is required for
better adjustment [12, 52]. With regard to surveys of
HRQOL in cancer patients, our findings indicate that
proxy reports differ significantly from patient reports,
and regression adjustment using sociodemographic and
clinical covariates has at minimal impact on this differ-
ence. It is possible that identifying and including add-
itional covariates predictive of patient illness may reduce
these differences, particularly because the fully adjusted
models only explained <20% of the variance of both out-
comes. However, even models that include symptoms as
predictors of HRQOL result in less than 30% of the vari-
ance in outcomes explained [53]. Similar levels of explana-
tory power are reported for paired studies evaluating
factors associated with proxy-patient concordance [54].
This study had several limitations. First, the CanCORS
data, while population-based and nationally representative,
were collected several years ago. However, there is no rea-
son that the models would not be valid when evaluating a
methodological issue such as evaluating proxy-patient
differences in HRQOL. Second, the data used in this paper
are cross-sectional; however, many population-based
surveys and most studies evaluating patient-proxy concord-
ance in HRQOL employ cross-sectional designs [5]. Third,
the CanCORS response rate was 51%; while not ideal, this
rate is similar to the response rates for other large
population-based national surveys such as the BRFSS [55]
that are used to inform health policy and practice. Finally,
although using ½ SD as a marker of clinical or minimally
important difference is common, it is not the only metric
for estimating a minimally important difference. Differences
of two to three points on the SF-12 have been considered
minimally important in studies with patients with prostate
cancer [56]. In a study with patients with extramedullary
spinal tumors, score differences of 2.8 points were proposed
as minimally important for the PCS and differences of 10.7
for the MCS [57]. Since minimal differences may vary by
population and context [58], the generalizability of these
varying thresholds to our study, which included patients
with lung and colorectal tumors, is not clear. We did not
identify a clearly established minimal difference threshold
for our survey population and context in the literature.
Nonetheless, in our study we identified large and persistent
differences that were only minimally affected by adjustment
for sociodemographic and clinical covariates.
Conclusions
In summary, proxy reports of patient HRQOL that are
used to substitute for otherwise missing patient reports
are clinically and statistically different from available pa-
tient reports. Adjustments using frequently employed
sociodemographic, clinical and comorbidity covariates
have a minimal effect on these differences. In situations
of high rates of proxy use, the effect of proxies can be
consequential, particularly if the results of such
estimates will be employed in performance measures or
used to inform policy decisions.
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